Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab consolidation after concurrent chemoradiotherapy in unresectable esophageal squamous cell carcinoma
ChiCTR2500115299Phase 3Completed
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing sintilimab consolidation with Control: observation after CCRT (2 arms). Primary endpoint: 3-year overall survival rate. Started Dec 2025; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500115299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115299.